Results 11 to 20 of about 569,881 (316)

Acute myeloid leukemia

HemaSphere, 2019
Acute myeloid leukemia (AML) occurs with a frequency of 3.5/1,000,000/year cases. AML patients have an invasion of diseased cells (blasts) medullary insufficiency, microenvironmental dysfunction, defects in the proliferation and function of the remaining
H. Döhner, Daniel J. Weisdorf, Clara D. Bloomfield   +2 more
openaire   +4 more sources

International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

Blood, 2022
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology.
D. Arber, A. Orazi, R. Hasserjian, M. Borowitz, K. Calvo, H. Kvasnicka, Sa A. Wang, A. Bagg, T. Barbui, S. Branford, C. Bueso-Ramos, J. Cortes, P. Dal Cin, C. Dinardo, H. Dombret, E. Duncavage, B. Ebert, E. Estey, F. Facchetti, K. Foucar, N. Gangat, U. Gianelli, L. Godley, N. Goekbuget, J. Gotlib, E. Hellström-Lindberg, G. Hobbs, R. Hoffman, E. Jabbour, J. Kiladjian, R. Larson, M. L. Le Beau, M. Loh, B. Löwenberg, E. Macintyre, L. Malcovati, C. Mullighan, C. Niemeyer, O. Odenike, S. Ogawa, A. Órfão, E. Papaemmanuil, F. Passamonti, K. Porkka, C. Pui, J. Radich, A. Reiter, M. Rozman, M. Rudelius, M. Savona, C. Schiffer, Annette Schmitt-Graeff, A. Shimamura, J. Sierra, W. Stock, R. Stone, M. Tallman, J. Thiele, H. Tien, A. Tzankov, A. Vannucchi, P. Vyas, A. Wei, O. Weinberg, A. Wierzbowska, M. Cazzola, H. Döhner, A. Tefferi   +67 more
semanticscholar   +1 more source

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

New England Journal of Medicine, 2022
BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia ...
P. Montesinos, C. Récher, S. Vives, E. Zarzycka, Jianxiang Wang, Giambattista Bertani, M. Heuser, R. Calado, A. Schuh, S. Yeh, S. Daigle, J. Hui, S. Pandya, D. Gianolio, S. de Botton, H. Döhner   +15 more
semanticscholar   +1 more source

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding.
S. Shimony, Maximilian F. Stahl, R. Stone   +2 more
semanticscholar   +1 more source

Recent advances in targeted therapies in acute myeloid leukemia

Journal of Hematology & Oncology, 2023
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell ...
R. Bhansali, K. Pratz, Catherine Lai
semanticscholar   +1 more source

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2023
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.
D. Pollyea, J. Altman, R. Assi, D. Bixby, A. Fathi, J. Foran, I. Gojo, Aric Hall, B. Jonas, Ashwin Kishtagari, J. Lancet, L. Maness, J. Mangan, G. Mannis, G. Marcucci, A. Mims, Kelsey Moriarty, Moaath K. Mustafa Ali, Jadee L. Neff, R. Nejati, R. Olin, M. Percival, A. Perl, Amanda C. Przespolewski, D. Rao, F. Ravandi, R. Shallis, P. Shami, E. Stein, R. Stone, K. Sweet, Swapna Thota, G. Uy, P. Vachhani, Carly J Cassara, Deborah A. Freedman-Cass, Katie Stehman   +36 more
semanticscholar   +1 more source

Acute myeloid leukemia: current progress and future directions

Blood Cancer Journal, 2021
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian, T. Kadia, C. Dinardo, N. Daver, G. Borthakur, E. Jabbour, G. Garcia-Manero, M. Konopleva, F. Ravandi   +8 more
semanticscholar   +1 more source

Advances in acute myeloid leukemia

British medical journal, 2021
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar   +1 more source

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

New England Journal of Medicine, 2020
BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman, Jacqueline S. Garcia, A. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, Jianxiang Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R. Lemoli, Kazuhito Yamamoto, S. Yoon, J. Jang, S. Yeh, M. Turgut, W. Hong, Ying Zhou, J. Potluri, K. Pratz   +29 more
semanticscholar   +1 more source

RUNX oncoproteins and miRNA networks [PDF]

, 2017
News on: An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells by Zaidi et al. Oncotarget. 2017; 8:39994-40005.
Borland, Gillian, Hay, Jodie, Neil, James C.   +2 more
core   +1 more source